JuliaReyes
Julia Reyes writes about pharmaceutical regulation, lobbying and US health policy. A graduate of UCLA's public policy programme, she is particularly interested in the relationship between drugmakers and their regulators.
Articles by Julia Reyes
Companies/September 22
Why is Biogen considered controversial?
Investigations/September 19
What was Aduhelm and why was its approval such a big deal?
Companies/September 14
Why is Eli Lilly considered controversial?
Drug Pipeline/September 2
Who controls the US insulin market?
Companies/July 31
What did the congressional investigation into Aduhelm find?
Investigations/July 29
Why were Aduhelm's clinical trial results considered unreliable?
Companies/July 24
What did Eli Lilly plead guilty to over Zyprexa?
Drug Pipeline/July 11
How much did insulin prices rise?
Companies/June 9
How did Biogen price Aduhelm, and what did the investigation say about it?
Investigations/June 6